Following genomic analysis revealed that low SGK1 expression was correlated with favorable outcome in multiple myeloma patients treated with bortezomib, indicating that SGK1 promotes tumor growth via raising resistance to ER stress. Here, SGK1 is linked to plasma cell myeloma.